Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
236 hedge funds and large institutions have $5.28B invested in Blueprint Medicines in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 82 increasing their positions, 81 reducing their positions, and 27 closing their positions.
43% more call options, than puts
Call options by funds: $31M | Put options by funds: $21.6M
20% more capital invested
Capital invested by funds: $4.39B → $5.28B (+$889M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
1% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 81
1% more funds holding
Funds holding: 234 → 236 (+2)
0.19% less ownership
Funds ownership: 103.81% → 103.62% (-0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$115M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$75.2M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$43.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$25.5M |
| 5 |
N
Natixis
Paris,
France
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$58M |
| 2 |
AG
Artal Group
Luxembourg
|
-$42.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$29M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$27.3M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$26.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HS
251
HighVista Strategies
Boston,
Massachusetts
| – | -$421K | -5,396 | Closed |
|
252
Bessemer Group
Woodbridge,
New Jersey
| – | -$398K | -5,100 | Closed |
|
253
Mercer Global Advisors
Denver,
Colorado
| – | -$320K | -4,102 | Closed |
|
254
Nomura Holdings
Tokyo,
Japan
| – | -$288K | -3,696 | Closed |
|
|
AAP
255
Ardsley Advisory Partners
Stamford,
Connecticut
| – | -$273K | -3,500 | Closed |
|
256
Walleye Capital
New York
| – | -$205K | -2,628 | Closed |
|
|
CG
257
Cutler Group
San Francisco,
California
| – | -$69.3K | -900 | Closed |
|
|
SF
258
Synovus Financial
Columbus,
Georgia
| – | -$5K | -63 | Closed |
|
|
TC
259
Truvestments Capital
Sarasota,
Florida
| – | -$4K | -55 | Closed |
|
|
SIM
260
Sonora Investment Management
Tucson,
Arizona
| – | -$2K | -26 | Closed |
|
|
PFWA
261
Paces Ferry Wealth Advisors
Atlanta,
Georgia
| – | +$231 | +3 | New |
|
BPMC Hedge Fund Activity: Q3 2020 in Review
236 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2020, worth a combined $5.28B — up 20% from $4.39B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BPMC positions and 27 closed out — a net gain of 2 holders — while 82 added to existing stakes and 81 trimmed.
The largest buyer was Cadian Capital Management, adding an estimated $115M. The largest seller was HealthCor Management, exiting entirely with an estimated $58M sold.
- 236 institutional investors held Blueprint Medicines (BPMC) as of Q3 2020, up from 234 in Q2 2020.
- Funds reported $5.28B of Blueprint Medicines stock for Q3 2020, up 20% quarter-over-quarter.
- 29 funds opened new Blueprint Medicines positions in Q3 2020 and 27 closed out, a net change of +2 holders.
- The largest Blueprint Medicines buyer in Q3 2020 was Cadian Capital Management, an estimated $115M added.
- The largest Blueprint Medicines seller in Q3 2020 was HealthCor Management, an estimated $58M sold.
Based on aggregated 13F filings for Q3 2020.